Posts tagged “Salix”
Salix revenue rises 62% in first quarter, beats Street
Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.
FDA delays decision on Salix drug to treat HIV-related diarrhea
Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.
FDA oushes back review for Salix constipation treatment
An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.
Raleigh-based Salix Pharmaceuticals to raise $600M
Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.
How long before Salix Pharmaceuticals hits $1B?
After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.
In the news: Visilink's LED wireless; MercuryGate grows; Salix drug trial; Furiex cuts losses; iContact donations; Software Toolbox update
Local tech briefs: Cary-based Visilink unveils LED-based wireless; Cary firm MercuryGate expands to Asia; Salix launches new drug trial; Furiex cuts its losses; iContact donates $200,000; Charlotte firm updates automation software.
Salix drug receives priority FDA review, but partner wants it back
The Raleigh firm is tied up in a law suit over the development of the drug that's intended to help AIDS patients suffering with diarrhea.
Salix's pill version of Relistor succeeds in phase 3; NDA expected in 2012
Salix released successful phase 3 clinical trial results for the oral version of Relistor and now plans to submit a new drug application for the compound in the middle of 2012.
Salix faces tough questions from FDA about expanded use of drug
Salix is preparing for new set of Xifaxan phase 3 clinical trials studying the irritable bowel syndrome indication, which puts approval about two years away. But first the company will meet with an FDA advisory panel on Wednesday, eight months after receiving the complete response letter from the agency declining approval on Xifaxan as a new IBS treatment.
FDA raises questions about Salix drug; shares fall 10%
Triangle-based Salix wants to expand use of its bowel drug but the FDA raised questions that concern an analyst who follows the company.
California drug firm terminates potential blockbuster deal with Salix
"Napo believes Salix has materially breached the collaboration agreement by unnecessarily stalling the advancement of this compound," Napo Pharmaceuticals says. "Most notably, Salix has failed to file an NDA one year after a highly successful phase 3 clinical trial or to prepare for commercial manufacture of the drug -- critical tasks that were fundamental to its responsibilities."
Salix acquires NJ pharma firm for $300M; earnings soar
"The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix's base business and provides immediate added revenue," says Salix CEO Carolyn Logan.
FDA to consider additional use for Salix drug
Salix and drug partner Progenics Pharmaceuticals want to expand Relistor's use to treat opioid-induded constipation in patients taking the drugs for non-cancer pain.
Salix faces a delay in OK for wider use of drug
Data from proposed irritable bowel syndrome drug Xifaxan faces further review, Salix says. The FDA rejected Xifaxan as IBS tgreatment in March.
Salix faces suit from drug development partner
The Raleigh-based company says that the suit's charges "are without merit."
E-mail Preferences
![[VIDEO]](http://wwwcache.wral.com/asset/business/2012/05/15/11105443/11105444-1337269517-80x60.jpg)
Could Facebook cue tech bubble?
![[VIDEO]](http://wwwcache.wral.com/asset/business/2012/05/15/11105443/11105445-1337253686-80x60.jpg)
Facebook 101: Examining a…
![[VIDEO]](http://wwwcache.wral.com/asset/business/2012/05/14/11100576/265788-facebook-80x60.jpg)
Buffett won't join Facebook IPO mania
![[VIDEO]](http://wwwcache.wral.com/presentation/v2/images/1x1.gif "http://wwwcache.wral.com/asset/business/2012/05/11/11091792/11091793-1336751325-80x60.jpg")
Japan's tech titans post record losses
FBI study reveals cyber crime trends
Community collaborates for Triangle Wiki
Video game conference is strictly…
Re-program speed dial before Saturday
Red Hat exec talks about company's $1B…
MedCity
- Healthcare innovation, convergence come together at MedCity CONVERGE
- Diabetes education uses video support network to improve outcomes
- GSK’s Deirdre Connelly dips toe into blogosphere. Will she take the plunge?
- Health 2.0 trends: depression as recovery obstacle, mobile health’s evolution
- Teen develops early stage, non-invasive pancreatic cancer detector, wins Intel science fair